A Study to Evaluate the Efficacy and Safety of AD-208

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AD-208 in Male Patients With Androgenetic Alopecia

The purpose of this study is to evaluate the efficacy and safety of AD-208.

The purpose of this study is to evaluate the efficacy and safety of AD-208 in male patients with androgenetic alopecia.

Inclusion Criteria:

• Male patients aged 18-50 years, inclusive
• Patients who meet the appropriate criteria according to the classification of hair loss
• Signed informed consent

Exclusion Criteria:

• Patients with hair loss disorders other than androgenetic alopecia
• Other exclusions applied